v3.26.1
Share-Based Compensation
 3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
The Company recognized share-based compensation in its Condensed Statements of Operations and Comprehensive Loss during the three months ended March 31, 2026 and 2025 as follows:
 Three Months Ended
March 31,
 20262025
Manufacture and supply$69 $100 
Research and development236 330 
Selling, general and administrative2,013 1,157 
Total share-based compensation expenses$2,318 $1,587 
Share-based compensation from:
Restricted stock units$1,655 $1,102 
Stock options663 485 
Total share-based compensation expenses$2,318 $1,587 
Share-Based Compensation Equity Awards
The following tables provide information about the Company’s restricted stock unit and stock option activity during the three month period ended March 31, 2026:
Restricted Stock Units
The following tables summarize the Company’s awards of service-based and market conditions vesting-based restricted stock units for the three month period ended March 31, 2026:
Restricted Stock Unit Awards (RSUs) - Service-based:Number of
Units		Weighted
Average
Grant Date Fair
Value
 (in thousands) 
Unvested as of December 31, 20252,684 $3.24 
Granted1,282 $4.29 
Vested(1,125)$2.32 
Forfeited(2)$4.14 
Unvested as of March 31, 20262,839 $4.08 
Expected to vest as of March 31, 20262,597 $4.08 
As of March 31, 2026, $8,931 of total unrecognized compensation expenses related to unvested service-based restricted stock units are expected to be recognized over a remaining weighted average period of 2.24 years. The service-based restricted stock units granted to employees are subject to a three-year graduated vesting schedule and are not subject to performance-based criteria other than continued employment.
Restricted Stock Unit Awards (RSUs) - Market conditions vesting-based:Number of
Units		Weighted
Average
Grant Date Fair
Value
 (in thousands) 
Unvested as of December 31, 20251,728 $2.55 
Granted— — 
Vested— — 
Forfeited— — 
Unvested as of March 31, 20261,728 $2.55 
Expected to vest as of March 31, 20261,661 $2.54 
As of March 31, 2026, $1,090 of unrecognized compensation expense related to unvested market condition vesting- based restricted stock units are expected to be recognized over a remaining weighted average period of 0.78 years.
The 2023 market conditions vesting-based restricted stock units vest based on a Performance Price measured as the 30-day average of the closing prices of the Common Stock as reported on the Nasdaq Global Market immediately prior to and including the last calendar day of the three-year performance period (which ends on the third anniversary of the grant date). To the extent the Performance Price is less than $1.75, the Vesting Percentage will be zero. To the extent the Performance Price is $1.75, the Vesting Percentage will be 50%. To the extent the Performance Price is $1.76 or greater, but less than $2.50, the Vesting Percentage will be a prorated amount between 50.01% and 99.99%, based on straight-line interpolation. To the extent the Performance Price is $2.50, the Vesting Percentage will be 100%. To the extent the Performance Price is $2.51 or greater, but less than $3.25, the Vesting Percentage will be a prorated amount between 100.01% and 149.99%, based on straight-line interpolation. To the extent the Performance Price is $3.25 or greater, the Vesting Percentage will be 150%. In no event will the Vesting Percentage exceed 150%.
The 2025 market conditions vesting-based restricted stock units were measured over a three-year performance period. The performance period is split into two pricing periods. The first pricing period commences on the grant date and ends on the calendar day immediately proceeding the second anniversary of the grant date. The second pricing period commences on the second anniversary of the grant date and ends on the third anniversary of the grant date, The performance price for the first pricing period is calculated based on the 30-day average price observed for the last 30 days of the first pricing period. The performance price for the second pricing period is calculated based on the highest 30-day average for any 30-day period throughout the second pricing period. To the extent the Performance Price is less than $6.00, the Vesting Percentage will be zero. To the extent the Performance Price is $6.00, the Vesting Percentage will be 50%. To the extent the Performance Price is $6.01 or greater, but less than $7.00, the Vesting Percentage will be a prorated amount between 50.01% and 99.99%, based on straight-line interpolation. To the extent the Performance Price is $7.00, the Vesting Percentage will be 100%. To the extent the Performance Price is $7.01 or greater, but less than $8.00, the Vesting Percentage will be a prorated amount between 100.01% and 149.99%, based on straight-line interpolation. To the extent the Performance Price is $8.00 or greater, the Vesting Percentage will be 150%. In no event will the Vesting Percentage exceed 150%.
The Company’s estimates of the fair value of the 2025 market conditions vesting-based awards at their grant or valuation dates were based on a Monte Carlo simulation and considered various variables and the following assumptions:
 Three Months Ended
March 31, 2025
Expected dividend yield0%
Expected volatility91.5%
Risk-free interest rate3.9%
Stock price at grant date
$2.65
Stock Option Awards:Number of
Options		Weighted Average
Exercise Price
 (in thousands)
Outstanding as of December 31, 20256,558 $5.59 
Granted946 4.29 
Exercised(1)0.88 
Forfeited/Expired(1)3.84 
Outstanding as of March 31, 20267,502 $5.42 
Expected to vest as of March 31, 20267,342 $5.45 
Exercisable as of March 31, 20265,441 $5.96 
The fair values of stock options granted were estimated using the Black-Scholes pricing model based on the following assumptions:
Three Months Ended
March 31, 2026
Expected dividend yield—%
Expected volatility98%
Expected term (years)6.1
Risk-free interest rate3.8%
The weighted average grant date fair value of stock options granted during the three months ended March 31, 2026 was $3.43. During the three months ended March 31, 2026, stock options were granted with a weighted average exercise price of $4.29.
As of March 31, 2026, $5,272 of unrecognized compensation expense related to non-vested stock options is expected to be recognized over a remaining weighted average period of 2.04 years.
2022 Inducement Equity Incentive Plan (number of units in thousands)
In accordance with Nasdaq Listing Rule 5635(c)(4), the Company adopted the 2022 Equity Inducement Plan approved by the Compensation Committee of the Board of Directors of the Company effective as of July 29, 2022. There were 75 service-based awards and 50 options granted under this Plan during the three months ended March 31, 2026. The options and service-based awards granted under this Plan are included in the tables above. As of March 31, 2026, 775 shares remained available for grant under this Plan.